Bridgebio Pharma Inc. (bbio 2.5 03/15/27)
13F holders, Q1 2025 (March 31)2holders −3
0new positions
3sold out
$1.14avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Bridgebio Pharma Inc. (bbio 2.5 03/15/27) in their 13F filings, down 3 from Q4 2024. 0 opened new positions and 3 sold out. The largest holders were Bank of New York Mellon Corp ($343K) and Jones Financial Companies LLLP ($1K).
- Company
- Bridgebio Pharma Inc. (bbio 2.5 03/15/27)
- CUSIP
- 10806XAB8
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $5.9M |
All 13F filers, Q4 2024 → Q1 2025: 5,666,000 shares sold, net −5,666,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Bank of New York Mellon Corp | 0.00% | No change | 300,000 | $343K |
| Jones Financial Companies LLLP | 0.00% | No change | 1,000 | $1K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.5 03/15/27) the manager owns.